Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Since immune checkpoint inhibitor (ICI) blockade has become standard therapy for many cancers, immune-related adverse events (irAEs) have increased. ICI-pneumonitis is infrequent but potentially fatal. In cases not responsive to corticosteroids, additional immunosuppression is recommended. Data for use of infliximab in ≥ grade 3 pneumonitis is sparse.

https://meridian.allenpress.com/innovationsjournals-JIPO/article/3/4/172/446353/Role-of-Infliximab-in-Immune-Checkpoint-Inhibitor
What if VIP becomes part of checkpoint-inhibitor treatment for cancers? —- The global adalimumab, infliximab, and etanercept market is expected to grow from $2.2 billion in 2019 to $2.27 billion in 2020 at a compound annual growth rate (CAGR) of 3.24%. The market is expected to recover and reach $7.50 billion in 2023 at a CAGR of 48.94%.

https://www.businesswire.com/news/home/20210204005555/en/Global-Adalimumab-Infliximab-and-Etanercept-Biosimilars-Market-Report-2020---ResearchAndMarkets.com

Pneumonitis (noo-moe-NIE-tis) is a general term that refers to inflammation of lung tissue. Technically, pneumonia is a type of pneumonitis because the infection causes inflammation. Pneumonitis, however, is usually used by doctors to refer to noninfectious causes of lung inflammation.

https://www.mayoclinic.org/diseases-conditions/pneumonitis/symptoms-causes/syc-20352623